Nab‑paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma

  • Authors:
    • Peter Mu‑Hsin Chang
    • Chi‑Tung Cheng
    • Ren‑Chin Wu
    • Yi‑Hsiu Chung
    • Kun‑Chun Chiang
    • Ta‑Sen Yeh
    • Chun‑Yu Liu
    • Ming‑Han Chen
    • Ming‑Huang Chen
    • Chun‑Nan Yeh
  • View Affiliations

  • Published online on: May 10, 2018     https://doi.org/10.3892/ol.2018.8690
  • Pages: 566-572
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Intrahepatic cholangiocarcinoma (IH‑CCA) is the second predominant hepatic malignancy worldwide. However, effective treatment strategies for IH‑CCA have not yet been developed. Nab‑paclitaxel may be an effective drug against IH‑CCA, a type of desmoid‑like tumor, and its antitumor effects may be attributable to its ability to disrupt the cancer‑associated fibroblasts. In the present study, MTT and Annexin‑V apoptosis detection kits were used to evaluate the efficacy of paclitaxel and nab‑paclitaxel against human cholangiocarcinoma KKU‑100 and KKU‑213 cell lines. A rat model of thioacetamide‑induced spontaneous desmoplastic IH‑CCA was used to compare the treatment response of four different drug regimens: Control, paclitaxel, nab‑paclitaxel and gemcitabine/oxaliplatin. Positron emission tomography and immunofluorescence analysis were used to measure the tumor volume and to study the resected tumor, respectively. In vitro, paclitaxel and nab‑paclitaxel induced anti‑proliferative effects in KKU‑100 and KKU‑M213 cells. With regards to the treatment regimes, only nab‑paclitaxel and gemcitabine/oxaliplatin induced antitumor effects in the rat model of thioacetamide‑induced IH‑CCA. The immunofluorescence study indicated that nab‑paclitaxel was more efficient in disrupting cancer‑associated fibroblasts than paclitaxel. In conclusion, nab‑paclitaxel is effective against IH‑CCA owing to its ability to markedly disrupt the desmoplastic stroma.
View Figures

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chang PM, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN, Yeh CN, et al: Nab‑paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncol Lett 16: 566-572, 2018.
APA
Chang, P.M., Cheng, C., Wu, R., Chung, Y., Chiang, K., Yeh, T. ... Yeh, C. (2018). Nab‑paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. Oncology Letters, 16, 566-572. https://doi.org/10.3892/ol.2018.8690
MLA
Chang, P. M., Cheng, C., Wu, R., Chung, Y., Chiang, K., Yeh, T., Liu, C., Chen, M., Chen, M., Yeh, C."Nab‑paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma". Oncology Letters 16.1 (2018): 566-572.
Chicago
Chang, P. M., Cheng, C., Wu, R., Chung, Y., Chiang, K., Yeh, T., Liu, C., Chen, M., Chen, M., Yeh, C."Nab‑paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma". Oncology Letters 16, no. 1 (2018): 566-572. https://doi.org/10.3892/ol.2018.8690